| 
Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).  | 
|   | 
 | 
 | 
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck  | 
|   | 
 | 
Consulting or Advisory Role - ARMO Biosciences; Celgene; Incyte; Merrimack; Oncogenex; Threshold Pharmaceuticals  | 
Research Funding - Aduro Biotech (Inst); Celgene (Inst); ImClone Systems (Inst); Infinity Pharmaceuticals (Inst); PharmaEngine (Inst); PRISM BioLab (Inst); Seagen (Inst)  | 
|   | 
 | 
Consulting or Advisory Role - Amgen; Sirtex Medical; Taiho Pharmaceutical  | 
Speakers' Bureau - Genentech  | 
Research Funding - Biomarin (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)  | 
Travel, Accommodations, Expenses - Amgen; Genentech; Lilly  | 
|   | 
 | 
Stock and Other Ownership Interests  - Abbvie; Amgen; Johnson & Johnson  | 
 | 
Consulting or Advisory Role - Halozyme; Taiho Pharmaceutical  | 
Research Funding - Aduro Biotech; Clovis Oncology; FibroGen; Immunomedics; Incyte; OncoMed; Theranostics Health  | 
|   | 
 | 
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; MedImmune; Merck; Plexxikon; Verastem  | 
Research Funding - AB Science; Aduro Biotech; Astellas Pharma; AstraZeneca; Bayer; Celgene; GlaxoSmithKline; Incyte; MedImmune; Merck; Verastem  | 
Expert Testimony - Aduro Biotech  | 
|   | 
 | 
Honoraria - Merrimack; Pfizer  | 
Consulting or Advisory Role - Merrimack; pfizer  | 
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Merrimack (Inst); Newlink Genetics (Inst); OncoMed (Inst); pfizer (Inst); Precision Therapeutics (Inst); Prometheus (Inst)  | 
Travel, Accommodations, Expenses - Axis Pharma  | 
|   | 
 | 
 | 
|   | 
 | 
Stock and Other Ownership Interests  - PhytoChem  | 
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Genentech/Roche; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical  | 
Speakers' Bureau - Celgene; Genentech/Roche; Novartis; Taiho Pharmaceutical  | 
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)  | 
|   | 
 | 
Research Funding - Aduro Biotech (Inst)  | 
|   | 
 | 
Honoraria - Celgene; Lilly; Merrimack  | 
Consulting or Advisory Role - Celgene; Merrimack  | 
Research Funding - Abbvie; Bayer; Celgene; Genentech/Roche; Lilly; Millennium  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Employment - Aduro Biotech  | 
Stock and Other Ownership Interests  - Aduro Biotech  | 
|   | 
 | 
Employment - Aduro Biotech  | 
Stock and Other Ownership Interests  - Aduro Biotech  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Employment - Aduro Biotech  | 
Stock and Other Ownership Interests  - Aduro Biotech; Bavarian Nordic; Exelixis  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Employment - Aduro Biotech  | 
Leadership - Aduro Biotech  | 
Stock and Other Ownership Interests  - Aduro Biotech  | 
Consulting or Advisory Role - Turnstone Bio  | 
Patents, Royalties, Other Intellectual Property - Aduro Biotech  | 
|   | 
 | 
Employment - Aduro Biotech  | 
Leadership - Aduro Biotech  | 
Stock and Other Ownership Interests  - Aduro Biotech  | 
Patents, Royalties, Other Intellectual Property - Aduro Biotech  | 
|   | 
 | 
Consulting or Advisory Role - Aduro Biotech; MedImmune; Vaccinex (Inst)  | 
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Roche  | 
Patents, Royalties, Other Intellectual Property - Aduro Biotech  | 
Travel, Accommodations, Expenses - Janssen  |